Faricimab 6 mg/0.05 mL Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 6 mg/0.05 mL
Reference Brands: Vabysmo (USA/EU)
Category: Opthalmology
Faricimab is a Opthalmology product available as Injection in strengths 6 mg/0.05 mL. It corresponds to the reference brand Vabysmo (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.
Product Description:
Faricimab (faricimab-svoa) is an advanced ophthalmic biologic therapy developed to treat serious degenerative retinal conditions that can lead to vision loss. It is a humanised bispecific monoclonal antibody designed to simultaneously target vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), two key pathways involved in abnormal blood vessel growth, leakage, and inflammation in the retina. By blocking these mechanisms, faricimab helps stabilise blood vessels, reduce fluid accumulation, and improve visual outcomes in patients with retinal diseases.
This therapy is primarily indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular oedema (DMO), and it is also being used in the management of retinal vein occlusion-related macular oedema. Administered through intravitreal injection by an eye specialist, faricimab offers a targeted approach to controlling disease progression while protecting retinal structure and function.
One of the key advantages of faricimab is its potential to reduce treatment burden compared with traditional anti-VEGF therapies, as many patients may require fewer injections and clinic visits while maintaining effective disease control. Due to its dual-pathway inhibition and strong clinical trial outcomes, faricimab has become an important advancement in the management of complex macular diseases.
Faricimab — third party manufacturing & bulk supply
Faricimab 6 mg/0.05 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Faricimab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Faricimab →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Faricimab is used for the treatment of retinal vascular diseases that can lead to vision loss. It is commonly prescribed for neovascular (wet) age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. It works by blocking proteins that cause abnormal blood vessel growth and leakage in the retina.
Faricimab-svoa is a humanized bispecific monoclonal antibody produced using recombinant DNA technology in mammalian cell culture. It is designed to simultaneously inhibit vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2).
The trade name of faricimab is Vabysmo.
Faricimab (Vabysmo) is developed and marketed by Genentech, a member of the Roche group.
The generic name is Faricimab, with the full nonproprietary name faricimab-svoa.
The main brand name available globally is Vabysmo.
Faricimab is manufactured in advanced biotechnology manufacturing facilities operated by Roche and its global network of biologics production sites, primarily in the United States and Europe for worldwide distribution.
Related Products
Artificial Tears
Strength:
0.3% to 1%
Form: Eye Drops/ Eye Gel/ Eye ointment
Reference Brands: Refresh Tears (USA/LATAM), Hylo-Tear (EU), Refresh Liquigel (India)
View Details
Tetrahydrozoline Hydrochloride
Strength:
0.05%
Form: Eye Drops
Reference Brands: Visine (USA/EU / LATAM), Ocuvis (India)
View Details
Quick Response Guaranteed | Verified Suppliers
